Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Liver Cirrhosis | Research

Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis

Authors: Haixia Yuan, Yingying Cao, Zhenjun Yu, Yue Huang, Fang Liu, Yanying Gao, Shaotian Qiu, Tao Han

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

There are few studies on acute-on-chronic liver failure (ACLF) in patients with recompensated cirrhosis. This study was aimed to investigate the clinical features of ACLF patients with recompensated cirrhosis.

Methods

A total of 461 ACLF patients were enrolled and divided into three groups: compensated, recompensated, and decompensated cirrhosis with ACLF. The baseline clinical data and 1-year survival rates were compared among the three groups.

Results

Compared with the decompensated group, in the recompensated group, the levels of hemoglobin, albumin, and serum sodium were significantly higher and the white blood cell count, international normalized ratio, and incidence of respiratory failure were significantly lower; there were no evident differences in other organ failures. The proportion of patients with ACLF grade 3 and 1-year survival rates significantly differed between the two groups. Conversely, compared with the compensated group, in the recompensated group, the platelet and total bilirubin levels were significantly lower and the proportion of patients with ACLF grade 1 was significantly higher. However, other clinical indicators or 1-year survival rates did not significantly differ between the two groups.

Conclusions

Compared with patients who developed ACLF with decompensated cirrhosis, those who developed ACLF with recompensated cirrhosis had a less severe condition, lower incidence of respiratory failure, and better 1-year prognosis. However, the baseline clinical features and prognosis were similar between ACLF patients with recompensated and compensated cirrhosis.

Trial registration

Chinese clinical trials registry: ChiCTR1900021539.
Appendix
Available only for authorised users
Literature
1.
go back to reference He ZY, Wang BQ, You H. Reversal of cirrhotic decompensation: recompensation. Chin J Hepatol. 2019;27(12):915–18. He ZY, Wang BQ, You H. Reversal of cirrhotic decompensation: recompensation. Chin J Hepatol. 2019;27(12):915–18.
2.
go back to reference Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of cirrhosis. J Clin Hepatol. 2019;27(11):846–65. Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of cirrhosis. J Clin Hepatol. 2019;27(11):846–65.
3.
go back to reference Monteiro S, Grandt J, Uschner F, Kimer N, Madsen J, Schierwagen R, et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut. 2021;70(2):379–87.PubMed Monteiro S, Grandt J, Uschner F, Kimer N, Madsen J, Schierwagen R, et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut. 2021;70(2):379–87.PubMed
4.
go back to reference Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-37,1437e1-9. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-37,1437e1-9.
5.
go back to reference Bihari C, Anand L, Rooge S, Kumar D, Saxena P, Shubham S, et al. Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver. Hepatology (Baltimore MD). 2016;64(4):1273–88.CrossRefPubMed Bihari C, Anand L, Rooge S, Kumar D, Saxena P, Shubham S, et al. Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver. Hepatology (Baltimore MD). 2016;64(4):1273–88.CrossRefPubMed
6.
go back to reference Piano S, Tonon M, Vettore E, Stanco M, Pilutti C, Romano A, et al. Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol. 2017;67(6):1177–84.CrossRefPubMed Piano S, Tonon M, Vettore E, Stanco M, Pilutti C, Romano A, et al. Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol. 2017;67(6):1177–84.CrossRefPubMed
7.
go back to reference Alves de Mattos A. Current indications for the use of albumin in the treatment of cirrhosis. Ann Hepatol. 2011;10(Suppl 1):15–20.CrossRef Alves de Mattos A. Current indications for the use of albumin in the treatment of cirrhosis. Ann Hepatol. 2011;10(Suppl 1):15–20.CrossRef
8.
go back to reference Naldi M, Giannone FA, Baldassarre M, Domenicali M, Caraceni P, Bernardi M, et al. A fast and validated mass spectrometry method for the evaluation of human serum albumin structural modifications in the clinical field. Eur J Mass Spectrom (Chichester). 2013;19(6):491–96.CrossRefPubMed Naldi M, Giannone FA, Baldassarre M, Domenicali M, Caraceni P, Bernardi M, et al. A fast and validated mass spectrometry method for the evaluation of human serum albumin structural modifications in the clinical field. Eur J Mass Spectrom (Chichester). 2013;19(6):491–96.CrossRefPubMed
9.
go back to reference Carvalho JR, Verdelho Machado M. New Insights about Albumin and Liver Disease. Ann Hepatol. 2018;17(4):547–60.CrossRefPubMed Carvalho JR, Verdelho Machado M. New Insights about Albumin and Liver Disease. Ann Hepatol. 2018;17(4):547–60.CrossRefPubMed
10.
go back to reference Bar-Or D, Bar-Or R, Rael LT, Gardner DK, Slone DS, Craun ML. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med. 2005;33(7):1638–41.CrossRefPubMed Bar-Or D, Bar-Or R, Rael LT, Gardner DK, Slone DS, Craun ML. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med. 2005;33(7):1638–41.CrossRefPubMed
11.
go back to reference Wang Y, Dong F, Sun S, Wang X, Zheng X, Huang Y, et al. Increased INR values predict accelerating deterioration and high short-term mortality among patients hospitalized with cirrhosis or Advanced Fibrosis. Front Med (Lausanne). 2021;8:762291.CrossRefPubMed Wang Y, Dong F, Sun S, Wang X, Zheng X, Huang Y, et al. Increased INR values predict accelerating deterioration and high short-term mortality among patients hospitalized with cirrhosis or Advanced Fibrosis. Front Med (Lausanne). 2021;8:762291.CrossRefPubMed
12.
go back to reference Angeli P, Wong F, Watson H, Gines P, Investigators C. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44(6):1535–42.CrossRefPubMed Angeli P, Wong F, Watson H, Gines P, Investigators C. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44(6):1535–42.CrossRefPubMed
14.
go back to reference Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41(1):32–9.CrossRefPubMed Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41(1):32–9.CrossRefPubMed
15.
go back to reference Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11(3):336–43.CrossRefPubMed Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11(3):336–43.CrossRefPubMed
16.
go back to reference Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40(4):802–10.CrossRefPubMed Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40(4):802–10.CrossRefPubMed
17.
go back to reference Li H, Chen LY, Zhang NN, Li ST, Zeng B, Pavesi M, et al. Characteristics, diagnosis and prognosis of Acute-on-chronic liver failure in Cirrhosis Associated to Hepatitis B. Sci Rep. 2016;6:25487.CrossRefPubMedPubMedCentral Li H, Chen LY, Zhang NN, Li ST, Zeng B, Pavesi M, et al. Characteristics, diagnosis and prognosis of Acute-on-chronic liver failure in Cirrhosis Associated to Hepatitis B. Sci Rep. 2016;6:25487.CrossRefPubMedPubMedCentral
18.
go back to reference Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272–84.CrossRefPubMed Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272–84.CrossRefPubMed
19.
go back to reference Yin S, Wang SJ, Gu WY, Zhang Y, Chen LY, Li H. Risk of different precipitating events for progressing to acute-on-chronic liver failure in HBV-related cirrhotic patients. J Dig Dis. 2017;18(5):292–301.CrossRefPubMed Yin S, Wang SJ, Gu WY, Zhang Y, Chen LY, Li H. Risk of different precipitating events for progressing to acute-on-chronic liver failure in HBV-related cirrhotic patients. J Dig Dis. 2017;18(5):292–301.CrossRefPubMed
Metadata
Title
Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis
Authors
Haixia Yuan
Yingying Cao
Zhenjun Yu
Yue Huang
Fang Liu
Yanying Gao
Shaotian Qiu
Tao Han
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Liver Cirrhosis
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02956-4

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.